Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Sarepta Therapeutic (SRPT) Eteplirsen NDA Filing on Track for Year-End, Needham & Company
August 7, 2014 11:55 AM EDTNeedham & Company analyst Chad Messer, Ph.D reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q2 results, noting Eteplirsen NDA filing is on track for year end.
Messer commented, "Management provided a detailed clinical and regulatory update on eteplirsen and follow-on exon skipping drugs for DMD on Sarepta's 2Q:14 earnings call. The bottom line is that all relevant activities are progressing well and the company remains on track to filing an... More
Sarepta Therapeutics (SRPT) CEO Chris Garabedian Speaks on CNBC
August 5, 2014 5:50 PM EDTSarepta Therapeutics (NASDAQ: SRPT) was active Tuesday following comment from CEO Chris Garabedian on CNBC.
... MoreSarepta Therapeutics (SRPT) Sees Upside
August 5, 2014 12:57 PM EDTSarepta Therapeutics (NASDAQ: SRPT) sees upside on volume. Shares up 2.9%.
... More